

Note: This document has been translated from the Japanese original for reference purposes only. In the event of any discrepancy between this translated document and the Japanese original, the original shall prevail.



October 15, 2026

Non-consolidated Financial Results for the Fiscal Year Ended August 31, 2026 [Japanese GAAP]

Company name: Chordia Therapeutics Inc.
 Listing: Tokyo Stock Exchange
 Security Code: 190A
 URL: <https://www.chorditherapeutics.com/>
 Representative: Hiroshi Miyake, CEO & Representative Director
 Inquiries: Masaru Okatani, CFO
 Telephone: +81-3-6661-9543
 Scheduled date for general shareholder meeting: November 26, 2026
 Scheduled date for submission of annual security report: November 25, 2026
 Preparation of supplementary material on financial results: Yes
 Holding of financial results briefing: Yes

(Yen amounts are rounded down to millions, unless otherwise noted)

1. Non-consolidated financial results for the Fiscal Year ended August 31, 2026 (from September 1, 2025 to August 31, 2026)

(1) Non-consolidated operating results (cumulative)

(Percentages indicate year-on-year changes)

	Business revenue		Operating income		Ordinary profit		Profit	
	Millions of yen	%	Millions of yen	%	Millions of yen	%	Millions of yen	%
August 31, 2026	-	-	-1,473	-	-1,450	-	-1,455	-
August 31, 2025	-	-	-1,789	-	-1,769	-	-1,785	-

	Basic earnings per share	Diluted earnings per share	Return on Equity	Ordinary Profit to Total Assets Ratio	Business revenue Operating profit Ratio
	Yen	Yen	%	%	%
August 31, 2026	-19.74	-	-66.9	-60.5	-
August 31, 2025	-26.03	-	-54.2	-48.4	-

(Reference) Equity in earnings of affiliates

August 31, 2026 -Millions of yen

August 31, 2025 -Millions of yen

NOTE 1. The diluted earnings per share are not stated because, although potential shares exist, the company recorded a net loss per share.

(2) Non-consolidated financial position

	Total Assets	Net Assets	Equity Ratio	Net Assets per Share
As of	Millions of yen	Millions of yen	%	Yen
August 31, 2026	2,114	1,925	90.7	24.83
August 31, 2025	2,681	2,437	90.8	35.29

(Reference) Equity

As of August 31, 2026

1,918 million yen

As of August 31, 2025

2,434 million yen

(3) Cash Flows

	Operating activities Cash flows from operating activities	Investing activities Cash flows from investing activities	Financing Activities Cash flows from financing activities	Cash and cash equivalents Balance at the end of year
	Millions of yen	Millions of yen	Millions of yen	Millions of yen
Year ended August 31, 2026	-1,418	-2	924	2,052
Year ended August 31, 2025	-1,836	-5	61	2,548

2. Cash dividends

	Dividend per share				
	End of first quarter	End of secondquarter	End of the third quarter	Term end	Total
	Yen	Yen	Yen	Yen	Yen
Fiscal year ended August 31, 2025	-	0.00	-	0.00	0.00
Fiscal year ended August 31, 2026	-	0.00	-	0.00	0.00
Fiscal year ending August 31, 2027 (Forecast)	-	0.00	-	0.00	0.00

3. Forecast of non-consolidated financial results for the fiscal year ending August 31, 2027 (from September 1, 2026 to August 31, 2027)

The Company has not provided a financial forecast for the fiscal year ending August 31, 2027, as it is currently difficult to reasonably estimate its financial results. For details regarding the reasons, please refer to page 4 of the attached materials, "1. Overview of Operating Results and Financial Position, (4) Future Outlook."

***Note**

- (1) Changes in accounting policies and changes or restatement of accounting estimates
 1. Changes in accounting policies due to revision of accounting standards: None
 2. Changes in accounting policies other than the above: None
 3. Changes in accounting estimates: None
 4. Restatement of revisions: None
- (2) Number of shares outstanding (common shares)
 1. Number of shares outstanding at the end of the period (including treasury stock)

FY8/2026	77,258,400 Shares
FY8/2025	68,988,800 Shares
 2. Number of treasury stock at the end of the period

FY8/2026	- Shares
FY8/2025	- Shares
 3. Average number of shares outstanding

FY8/2026	73,717,523 Shares
FY8/2025	68,607,945 Shares

* Financial results are not subject to audit by a certified public accountant or an auditing firm.

* Proper use of earnings forecasts, and other special matters
(Cautionary Statement Regarding Forward-Looking Statements)

The forecasts presented above are based on information currently available to the Company and contain a number of uncertainties. Actual results may differ from the above forecasts due to changes in business performance and other factors. For important information regarding the use of the financial forecasts, please refer to page 4 of the attached materials, “1. Overview of Operating Results and Financial Position, (4) Future Outlook.”

<How to Obtain Supplementary Materials on Financial Results and Information on the Financial Results Briefing>

The Company plans to hold a financial results briefing for institutional investors and analysts on Thursday, October 15, 2026. The presentation materials to be used at the briefing are scheduled to be posted on the Company’s website promptly after the briefing.

Attached Material

Index

1 . Qualitative information regarding financial results for the fiscal year ended August 31, 2026	2
(1) Explanation of operating results	2
(2) Explanation of financial position	3
(3) Explanation of cash flow.....	4
(4) Explanation of earnings forecasts and other forward-looking statements.....	4
(5) Material Uncertainty Related to Going Concern	4
2 . Basic principle on the choice of accounting standards.....	4
3 . Financial statement and significant notes thereto	5
(1) Balance sheet.....	5
(2) Statement of income.....	6
(3) Statement of Changes in Net Assets	7
(4) Cash Flows.....	9
(5) Notes to financial statements.....	10
Notes on premise of going concern	10
Notes on Share of Profit (Loss) of Entities Accounted for Using Equity Method	10
Notes on Segment Information.....	10
Notes on per share information.....	10
Note on Significant Subsequent Events.....	11

1. Qualitative information regarding financial results for the fiscal year ended August 31, 2026

(1) Explanation of operating results

The Company aspires to build a world where people can feel hope for tomorrow under its slogan of “Tomorrow is Another day,” by delivering first-in-class anticancer drugs from Japan to patients as quickly as possible. With a vision to grow into a Japan-originated, R&D-driven pharmaceutical company by 2030, the Company is focusing its business on oncology, an area with high unmet medical needs. In particular, the Company is committed to the research and development of first-in-class small-molecule drugs with novel mechanisms of action. These first-in-class drugs are expected to demonstrate unique benefits compared with existing therapies and have the potential to significantly change current treatment paradigms. The Company has been advancing its business with the goal of bringing hope to patients who are anxious about the progression of cancer due to insufficient efficacy of existing treatments, by offering new treatment options that can control disease progression.

During the fiscal year, the Japanese economy remained resilient, with personal consumption holding firm amid continued wage growth, while the pace of increases in food prices showed signs of slowing. With respect to the external environment, although uncertainty surrounding U.S. trade policy remains, excessive disruption is gradually being avoided. On the other hand, downside risks to the global economy persist, with concerns over a deterioration in export conditions in major economies, including China and Europe. In addition, heightened geopolitical risks in recent years have affected supply chains and resource prices, further increasing uncertainty surrounding overall corporate activity.

Under these circumstances, in the pharmaceutical and biotechnology industries in which the Company operates, major global pharmaceutical companies continue to review their supply chains in light of geopolitical risks and other factors, while research and development investment and business development activities remain ongoing. At the same time, a cautious approach to investment decisions has also been observed, and the business environment surrounding the Company remains uncertain.

With regard to current geopolitical risks, including the situation in the Middle East, the Company is not aware of any events that, as of this time, have a material impact on its business operations or financial results.

Under these circumstances, we have been advancing research and development of five pipeline programs, with a focus on the CLK inhibitor CTX-712, for which the International Nonproprietary Name (INN) is rogocekib (“rogocekib”).

rogocekib is a first-in-class, selective, orally available small-molecule inhibitor of CDC2-like kinase (CLK), a key regulator of RNA splicing that plays an important role in cell proliferation. In addition to receiving Orphan Drug Designation (ODD) from the U.S. Food and Drug Administration (FDA) for the treatment of acute myeloid leukemia (AML), rogocekib was also designated as an orphan drug by the Ministry of Health, Labour and Welfare (MHLW) in Japan in August 2026 for the treatment of relapsed or refractory acute myeloid leukemia (AML).

The Company is currently conducting a Phase 1/2 clinical trial in patients with relapsed or refractory acute myeloid leukemia and myelodysplastic syndromes, which was initiated in the United States in 2023. Based on data from 42 patients, the Safety Review Committee confirmed dosing regimens that met the safety and efficacy criteria for proceeding to the expansion cohort, and the Initial Expansion cohort (“IE”) commenced in March 2026.

The expansion cohort is planned to be conducted in two stages, IE and Additional Expansion (“AE”), in accordance with the FDA’s Project Optimus guidance. In IE, the Company plans to evaluate the safety and efficacy of multiple dosing regimens in 28 patients. As of the end of August 2026, 27 patients had been enrolled. Subsequently, in September 2026, enrollment of all 28 patients planned for IE was completed.

As a result, as of the end of September 2026, a total of 70 patients had been enrolled in this trial, including 42 patients in the dose-escalation part. Including the 60 patients enrolled in the Phase 1 clinical trial in Japan, for which enrollment has already been completed, a total of 130 patients have been enrolled across Japan and the United States.

Cumulative Number of Patients Enrolled in rogocekib Clinical Trials (as of the end of September 2026)

Clinical Trial (Patient Enrollment Status)	Country	Number of Patients Enrolled
Phase 1 Clinical Trial (Completed)	Japan	60 (Note)
Phase 1/2 Clinical Trial: Dose-Escalation Cohort (Completed)	U.S.	42
Phase 1/2 Clinical Trial: IE Cohort (Completed)	U.S.	28
Total		130

(Note) 46 had solid tumors, 12 had acute myeloid leukemia, and two had myelodysplastic syndromes.

Going forward, based on the results of IE, the Company plans to proceed to AE using the selected dosing regimen(s) and in the selected cancer type(s), with the aim of further evaluating safety and efficacy in preparation for the Phase 2 clinical trial. Based on a comprehensive evaluation of the results of the AE cohort, the Company plans to determine the Recommended Phase 2 Dose (RP2D) and the cancer type(s) to be evaluated in the Phase 2 clinical trial. At present, the Company plans to complete the evaluation of the AE cohort around mid-2027 and, based on the results, finalize the design and initiation of the Phase 2 clinical trial.

The future development plan may be subject to change depending on the progress of development, the external environment, and discussions with regulatory authorities. The Company will continue to advance research and development under an appropriate development plan with the aim of providing patients with a new treatment option.

Regarding ocipumaltib, a MALT1 inhibitor (“ocipumaltib”), the International Nonproprietary Name (INN) “ocipumaltib” has been published by the World Health Organization (WHO) as a recommended INN (rINN). In 2020, we entered into a license agreement with Ono Pharmaceutical Co., Ltd. (“Ono”), under which Ono conducted Phase 1 clinical trials in the U.S. and Japan. Subsequently, on April 28, 2025, we received notice from Ono that the clinical trials would be discontinued for strategic reasons. In February 2026, we entered into a termination agreement with Ono setting forth the specific procedures and detailed terms for the transfer of data. Under the agreement, the clinical trial data and other related data were transferred to us free of charge, and upon termination of the license agreement, we regained all worldwide rights to ocipumaltib.

We intend to fully utilize the clinical trial data obtained and are exploring a broad range of strategic options for the potential re-initiation of the development of ocipumaltib. Through business development activities, including potential out-licensing, we will seek to further enhance the value of our pipeline.

Regarding CTX-439, a CDK12 inhibitor currently in the preclinical stage (“CTX-439”), the GCN2 inhibitor (“GCN2”), and the fifth pipeline program (target undisclosed), we are continuing in-house research utilizing grants from the Japan Agency for Medical Research and Development (AMED) and other sources. However, as we are currently focusing our research and development resources on rogocekib, we are also actively exploring a broad range of strategic options for CTX-439 and GCN2, including early-stage partnering.

In addition, with the aim of further enhancing the value of our pipeline, we are exploring the potential of our compounds in disease areas beyond oncology through collaborative research and other initiatives. In 2025, we initiated separate collaborative research projects with D. Western Therapeutics Institute, Inc. and Senju Pharmaceutical Co., Ltd., each involving a different compound of the Company, to explore their potential as treatments for ophthalmic diseases, and these research activities are ongoing.

With respect to patents, the substance patent for rogocekib has been granted in 51 countries. Patents related to the identification of biomarkers in solid tumors and the use of rogocekib in combination with approved anticancer drugs remain under examination. For CTX-177, the substance patent has been granted in 18 countries, with one additional country added, and the manufacturing process patent has been granted in two countries, with one additional country added. A patent related to the use of CTX-177 in combination with approved anticancer drugs also remains under examination. For CTX-439, the substance patent has been granted in 51 countries, with one additional country added, while the substance patent for GCN2 has been granted in 50 countries, with one additional country added.

As a result of the above business activities, there was no business revenue for the fiscal year (same as the previous fiscal year). Regarding business expenses, research and development expenses totaled 1,154 million yen (down 19.0% year-on-year), and selling, general and administrative expenses totaled 318 million yen (down 12.5% year-on-year).

As a result, operating loss for the period totaled 1,473 million yen (operating loss of 1,789 million yen for the previous fiscal year), ordinary loss totaled 1,450 million yen (ordinary loss of 1,769 million yen for the previous fiscal year), and net loss totaled 1,455 million yen (net loss of 1,785 million yen for the previous fiscal year).

The Company operates only one business segment (i.e., the pharmaceutical business), and therefore there are no segment-based operating results to report.

(2) Explanation of financial position

1) Assets, liabilities and net assets

Assets

Assets as of August 31, 2026, totaled 2,114 million yen, a decline of 566 million yen compared with the end of the previous fiscal year. Current assets totaled 2,102 million yen, a decline of 566 million yen compared with the end of the previous fiscal year. The main factor was a decline of 496 million yen in cash and deposits.

Liabilities

Liabilities as of August 31, 2026, totaled 188 million yen, a decline of 55 million yen compared with the end of the previous fiscal year. Current liabilities totaled 188 million yen, a decline of 55 million yen compared with the end of the previous fiscal year. The main factor was a decline of 26 million yen in accounts payable-other. There are no non-current liabilities.

Net assets

Net assets as of August 31, 2026, totaled 1,925 million yen, a decline of 511 million yen compared with the end of the previous fiscal year. The main factor was an increase of 469 million yen in share capital and an increase of 6,052 million yen in retained earnings, while capital surplus decreased by 7,038 million yen.

(3) Explanation of cash flow

Cash and cash equivalents (“funds”) at the end of the current fiscal year amounted to 2,052 million yen, down 496 million yen from the end of the previous fiscal year. The status of each cash flow and its main factors are as follows.

Cash flows from operating activities

Funds used in operating activities for the current fiscal year amounted to 1,418 million yen (1,836 million yen was used in the previous fiscal year). This was mainly due to the recording of loss before income taxes of 1,452 million yen.

Cash flows from investment activities

Funds used in investing activities for the current fiscal year amounted to 2 million yen (5 million yen was used in the previous fiscal year).

Cash flows from financing activities

Funds provided by financing activities for the current fiscal year amounted to 924 million yen (61 million yen was provided in the previous fiscal year). This was mainly due to proceeds of 927 million yen from the issuance of shares upon exercise of share acquisition rights.

(4) Explanation of earnings forecasts and other forward-looking statements

We will continue to advance the Phase 1/2 clinical trial of rogocekib in the United States while considering and preparing for its development as a multinational clinical trial involving Japan, following its selection for AMED’s GRiT program. In addition, with the aim of maximizing the value of rogocekib, we will steadily advance its development while maintaining various strategic options, including potential future business partnerships. For other pipeline programs, while focusing our research and development resources on rogocekib, we will continue to advance in-house research utilizing grants and explore opportunities for new business partnerships. Under these circumstances, our financial results may fluctuate significantly depending not only on the progress of clinical trials but also on the success or failure of business partnerships and the timing of the recognition of upfront payments and other related revenue. As we continue to maintain various strategic options, including potential future business partnerships, with the aim of maximizing the value of rogocekib, it is difficult to reasonably estimate the impact on our financial results at this time. Accordingly, we have not disclosed our full-year financial forecast for the fiscal year ending August 31, 2027.

In addition, in September 2026, a research and development project related to rogocekib was selected under GRiT (Global Research and Development Support Program for Drugs for Intractable and Rare Diseases), a funding program of the Japan Agency for Medical Research and Development (AMED). Through this selection, we expect to receive support of up to 1.5 billion yen for a portion of our research and development expenses. We will continue to advance the global development of rogocekib while utilizing this program.

(5) Material Uncertainty Related to Going Concern

We are a drug discovery venture company engaged in the research and development of novel anticancer drugs with the aim of commercialization. Drug discovery requires advanced expertise and substantial investment and typically involves a long lead time before monetization. As a result, we continue to incur operating losses and negative operating cash flows, including material operating losses and negative operating cash flows, which raise substantial doubt about our ability to continue as a going concern.

In response to this situation, we are focusing our management resources on our most promising pipeline candidate, rogocekib, to accelerate its development. For other pipeline programs, we intend to continue controlling costs while strategically exploring options, including business collaborations with other companies.

As of the end of the current fiscal year, we held cash and deposits totaling 2,052 million yen, which we believe is sufficient to continue our business operations for the next 12 months. In addition, in September 2026, we issued the 12th Series of Share Acquisition Rights (with exercise price adjustment clauses) to secure funding for the future development of rogocekib. This enables us to maintain a flexible funding structure to meet future capital needs.

Furthermore, in September 2026, a research and development project related to rogocekib was selected under a funding program of the Japan Agency for Medical Research and Development (AMED), and we expect to receive support for a portion of our research and development expenses going forward.

Based on the above, we believe there is no material uncertainty regarding the assumption of a going concern.

2. Basic principle on the choice of accounting standards

For the time being, the Company intends to prepare its financial statements in accordance with Japanese generally accepted accounting principles (Japanese GAAP), taking into consideration the comparability of financial statements from period to period and between companies. With regard to the application of International Financial Reporting Standards (IFRS), the Company intends to respond appropriately, taking into account various circumstances both in and outside Japan.

3. Financial statement and significant notes thereto

(1) Balance sheet

(Thousands of yen)

	As of August 31, 2025	As of August 31, 2026
Assets		
Current assets		
Cash and deposits	2,548,955	2,052,273
Advance payments	9,723	275
Prepaid expenses	24,903	17,425
Others	85,450	32,441
Total current assets	2,669,033	2,102,416
Non-Current assets		
Property, plant and equipment		
Tools, furniture and fixtures	10,477	10,477
Accumulated depreciation	-10,477	-10,477
Tools, furniture, and fixtures, net	0	0
Total property, plant and equipment	0	0
Investments and other assets		
Others	12,316	11,997
Total investments and other assets	12,316	11,997
Total non-current assets	12,316	11,997
Total assets	2,681,349	2,114,414
Liabilities		
Current liabilities		
Accounts payable-other	120,009	93,481
Accrued expenses	645	1,001
Income taxes payable	28,681	9,114
Others	95,002	85,242
Total current liabilities	244,338	188,840
Total liabilities	244,338	188,840
Net assets		
Shareholders' equity		
Share capital	876,270	1,345,823
Capital surplus	9,065,871	2,027,777
Retained earnings	-7,507,647	-1,455,144
Total shareholders' equity	2,434,495	1,918,457
Share acquisition rights	2,515	7,116
Total net assets	2,437,010	1,925,573
Total liabilities and net assets	2,681,349	2,114,414

(2) Statement of income

(Thousands of yen)

	Ended August 31, 2025 (September 1, 2024 To August 31, 2025)	Ended August 31, 2026 (September 1, 2025 To August 31, 2026)
Business revenue	—	—
Cost of sales		
Research and development expense	1,425,309	1,154,784
Selling, general and administrative expenses	364,471	318,986
Total operating expenses	1,789,781	1,473,770
Operating profit or loss(-)	-1,789,781	-1,473,770
Non-operating income		
Grant income	23,090	56,004
Others	918	271
Total non-operating income	24,009	56,275
Non-operating expenses		
Stock Issuance Cost	—	6,423
Share acquisition rights issuance expenses	—	15,224
Foreign exchange losses	3,897	10,368
Others	0	616
Total non-operating expenses	3,897	32,633
Ordinary profit or loss(-)	-1,769,669	-1,450,127
Extraordinary losses		
Impairment loss	13,777	2,596
Total extraordinary losses	13,777	2,596
Profit or Loss(-) before income taxes	-1,783,447	-1,452,724
Income taxes	2,420	2,420
Total income taxes	2,420	2,420
Net profit or loss(-)	-1,785,867	-1,455,144

(3) Statement of Changes in Net Assets

Previous fiscal year (September 1, 2024 to August 31, 2025)

(Unit: thousand yen)

	Shareholders' equity					
	Share capital	Capital surplus			Retained earnings	
		Capital reserve	Other capital surplus	Total capital surplus	Other retained earnings Retained earnings brought forward	Total retained earnings
Balance at the beginning of current period	845,270	6,162,207	2,872,664	9,034,871	-5,721,780	-5,721,780
Changes of items during the period						
Issuance of new shares (exercise of share acquisition rights)	31,000	31,000		31,000		
Net income					-1,785,867	-1,785,867
Net changes of items other than shareholders' equity						
Total changes of items during the period	31,000	31,000	—	31,000	-1,785,867	-1,785,867
Balance at the end of current period	876,270	6,193,207	2,872,664	9,065,871	-7,507,647	-7,507,647

	Shareholders' equity	Share acquisition rights	Total net assets
	Total shareholders' equity		
Balance at the beginning of current period	4,158,362	2,935	4,161,297
Changes of items during the period			
Issuance of new shares (exercise of share acquisition rights)	62,000		62,000
Net income	-1,785,867		-1,785,867
Net changes of items other than shareholders' equity		-420	-420
Total changes of items during the period	-1,723,867	-420	-1,724,287
Balance at the end of current period	2,434,495	2,515	2,437,010

Current fiscal year (September 1, 2025 to August 31, 2026)

(Unit: thousand yen)

	Shareholders' equity					
	Share capital	Capital surplus			Retained earnings	
		Capital reserve	Other capital surplus	Total capital surplus	Other retained earnings Retained earnings brought forward	Total retained earnings
Balance at the beginning of current period	876,270	6,193,207	2,872,664	9,065,871	(7,507,647)	(7,507,647)
Changes of items during the period						
Issuance of new shares (exercise of share acquisition rights)	469,553	469,553		469,553		
Capital reduction		(4,634,982)	4,634,982	—		
Deficit disposition			(7,507,647)	(7,507,647)	7,507,647	7,507,647
Net loss					(1,455,144)	(1,455,144)
Net changes of items other than shareholders' equity						
Total changes of items during the period	469,553	(4,165,429)	(2,872,664)	(7,038,093)	6,052,502	6,052,502
Balance at the end of current period	1,345,823	2,027,777	—	2,027,777	(1,455,144)	(1,455,144)

	Shareholders' equity Total shareholders' equity	Share acquisition rights	Total net assets
Balance at the beginning of current period	2,434,495	2,515	2,437,010
Changes of items during the period			
Issuance of new shares (exercise of share acquisition rights)	939,106		939,106
Capital reduction	—		—
Deficit disposition	—		—
Net loss	(1,455,144)		(1,455,144)
Net changes of items other than shareholders' equity		4,600	4,600
Total changes of items during the period	(516,037)	4,600	(511,437)
Balance at the end of current period	1,918,457	7,116	1,925,573

(4) Cash flows

(Unit: thousand yen)

	Previous fiscal year (From September 1, 2024, to August 31, 2025)	Current fiscal year (From September 1, 2025, to August 31, 2026)
Cash flows from operating activities		
Income (loss) before income taxes	-1,783,447	-1,452,724
Depreciation and amortization	2,702	—
Impairment Loss	13,777	2,596
Stock issuance expenses	—	6,423
Share acquisition rights issuance expenses	—	15,224
Grant income	-23,090	-56,004
Decrease (increase) in prepaid expenses	13,251	7,477
(Increase) decrease in advance payments	49,934	9,448
Decrease (increase) in long-term prepaid expenses	3,465	—
Increase (decrease) in accrued liabilities	-262,418	-28,598
Other	69,049	33,551
subtotal	-1,916,774	-1,462,605
Amount of grants received	82,272	46,490
Income taxes paid	-2,420	-2,420
Cash flows from operating activities	-1,836,921	-1,418,534
Cash flows from investing activities		
Payments for purchase of property, plant and equipment	-5,327	-2,596
Other	—	318
Cash flows from investing activities	-5,327	-2,277
Cash flows from financing activities		
Proceeds from issuance of shares upon exercise of share acquisition rights	61,580	927,465
Payments for issuance of share acquisition rights	—	-3,335
Cash flows from financing activities	61,580	924,129
Net increase (decrease) in cash and cash equivalents	-1,780,668	-496,681
Cash and cash equivalents at beginning of year	4,329,624	2,548,955
Cash and cash equivalents at end of year	2,548,955	2,052,273

(5) Notes to financial statements

Notes on premise of going concern

Not applicable.

Notes on Share of Profit (Loss) of Entities Accounted for Using Equity Method

Not applicable.

Notes on Segment Information

[Segment Information]

I. Previous fiscal year (from September 1, 2024 to August 31, 2025)

Disclosure of this information is omitted because the Company operates a single segment in the pharmaceutical business.

II. Current fiscal year (from September 1, 2025 to August 31, 2026)

Disclosure of this information is omitted because the Company operates a single segment in the pharmaceutical business.

Notes on per share information

	Previous Fiscal Year (From September 1, 2024, to August 31, 2025)	Current Fiscal Year (From September 1, 2025, to August 31, 2026)
Net Assets per Share	35.29 yen	24.83 yen
Net Income (Loss) per Share	-26.03 yen	-19.74 yen

NOTE 1. The diluted earnings per share are not stated because, although potential shares exist, the company recorded a net loss per share.

2. The basis for the calculation of net income per share is as follows:

	Previous Fiscal Year (From September 1, 2024, to August 31, 2025)	Current Fiscal Year (From September 1, 2025, to August 31, 2026)
Net Income (Loss)	-1,785,867 thousand yen	-1,455,144 thousand yen
Amount Not Attributable to Common Shareholders	—	—
Net Income (Loss) Attributable to Common Shareholders	-1,785,867 thousand yen	-1,455,144 thousand yen
Average Number of Common Shares Outstanding During the Period	68,607,945 shares	73,717,523 shares
Potential Shares Not Included in the Calculation of Diluted Net Income per Share Due to Lack of Dilutive Effect	7 types of share acquisition rights (5,727,000 shares)	10 types of share acquisition rights (14,125,400 shares)

Note on Significant Subsequent Events

1. Issuance of Share Acquisition Rights through Third-Party Allotment

At a meeting of the Board of Directors held on August 24, 2026, the Company passed a resolution to issue the 12th Series Share Acquisition Rights with exercise price adjustment clauses (with suspension designation clauses) by way of third-party allotment. Payment for the full subscription amount of such rights was completed on September 9, 2026. The principal terms are as follows:

Allotment Date	September 9, 2026
Total Number of Rights	184,220 units 12th Series: 184,220 units
Issue Price (Subscription Amount)	Total: ¥6,079,260 12th Series: ¥6,079,260 (¥33 per unit)
Type and Number of Shares Subject to Share Acquisition Rights	Common stock: 18,422,000 shares (100 shares per share acquisition right) 12th Series: 18,422,000 shares
Estimated Net Proceeds	¥1,506,683,260 (Note)
Capital Increase	The amount of capital increase upon exercise shall be determined by applying 50% to the maximum increase calculated in accordance with Article 17, Paragraph 1 of the Corporate Accounting Regulations. Any fraction less than one yen shall be rounded up. The amount of capital reserve increase shall be the difference between the maximum increase and the capital increase.
Initial Exercise Price and Adjustment Clause	Initial Exercise Price 12th Series: ¥82 From September 11, 2026 onward, the exercise price will be adjusted to an amount equal to 90% of the closing price of the Company's common shares in regular trading on the Tokyo Stock Exchange, Inc. (the "TSE") on the trading day immediately preceding the date on which notice of each exercise request for the share acquisition rights is given (or, if there is no closing price on such day, the closing price on the immediately preceding trading day; hereinafter referred to as the "TSE Closing Price"), rounded up to the nearest ¥0.01. However, if the exercise price calculated as described above would be lower than the minimum exercise price, the adjusted exercise price will be the minimum exercise price.
Exercise Period	12th Series: September 11, 2026 – September 8, 2028
Method of Offering or Allotment and Allottees	Third-party allotment to Nomura Securities Co., Ltd.
Use of Funds	To fund expansion cohort implementation and drug-drug interaction study costs in the Phase 1/2 clinical trial of rogocekib

(Note) The estimated net proceeds figure is based on deducting issuance-related costs from the total subscription amount plus the value of assets to be contributed upon exercise (assuming full exercise at the initial exercise price, which is the TSE Closing Price on the trading day immediately preceding the date of the resolution to issue the share acquisition rights). If the exercise price is adjusted, the actual proceeds may increase or decrease. In addition, if not all of the share acquisition rights are exercised during the exercise period, or if any share acquisition rights acquired by the Company are cancelled, the actual proceeds will decrease.

2. Capital Increase through Exercise of the 12th Series Share Acquisition Rights

After the end of the current fiscal year, between September 11, 2026 and September 30, 2026, a portion of the 12th Series Share Acquisition Rights were exercised as follows:

(1) Type and number of shares issued:	Common stock: 100,000 shares
(2) Increase in Capital Stock:	3,121 thousand
(3) Increase in Capital Reserve:	3,121 thousand

As a result, as of September 30, 2026, the total number of issued shares is 77,358,400 shares, the capital stock is 1,348,945 thousand yen, and the capital reserve is 2,030,899 thousand yen.